VIR * Stock Overview
An immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vir Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$172.00 |
| 52 Week High | US$172.00 |
| 52 Week Low | US$172.00 |
| Beta | 0.38 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| VIR * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how VIR * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how VIR * performed against the MX Market.
Price Volatility
| VIR * volatility | |
|---|---|
| VIR * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: VIR * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VIR *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 576 | Marianne De Backer | www.vir.bio |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
Vir Biotechnology, Inc. Fundamentals Summary
| VIR * fundamental statistics | |
|---|---|
| Market cap | Mex$22.47b |
| Earnings (TTM) | -Mex$10.43b |
| Revenue (TTM) | Mex$2.06b |
10.9x
P/S Ratio-2.2x
P/E RatioIs VIR * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIR * income statement (TTM) | |
|---|---|
| Revenue | US$118.80m |
| Cost of Revenue | US$451.90m |
| Gross Profit | -US$333.10m |
| Other Expenses | US$267.65m |
| Earnings | -US$600.75m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.47 |
| Gross Margin | -280.38% |
| Net Profit Margin | -505.67% |
| Debt/Equity Ratio | 0% |
How did VIR * perform over the long term?
See historical performance and comparison